Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder
ثبت نشده
چکیده
Health technology The study examined two selective serotonin re-uptake inhibitors (SSRIs), escitalopram and sertraline, for the treatment of major depressive disorder (MDD). Escitalopram was initially given at 10 mg/day; the dose was assumed to increase to 20 mg/day if the patient did not respond to the initial dose. Sertraline was initially given at 50 mg/day; dose titration to 100, 150 and 200 mg/day was assumed for patients not responding to lower dosages.
منابع مشابه
Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder.
OBJECTIVE To construct a cost-utility model comparing escitalopram with sertraline in the treatment of major depressive disorders. METHODS A decision analytic model was created to compare the cost-utility of these two antidepressants from the perspective of a managed-care organization. The model was designed to compare 10-20 mg/day of escitalopram to 50-200 mg/day of sertraline. Benefits (uti...
متن کاملEconomic evaluation of resistant major depressive disorder treat-ment in Iranian population: a comparison between repetitive Transcranial Magnetic Stimulation with electroconvulsive
Background: It is estimated that major depression disorders constitute 8.2% of years lived with disability (YLDs) globally. The repetitive Transcranial Magnetic Stimulation (rTMS) and Electroconvulsive Therapy (ECT) are two relative common interventions to treat major depressive disorders, especially for treatment resistant depression. In this study the cost- effectiveness and cost-utility of r...
متن کاملCost-effectiveness evaluation of escitalopram in major depressive disorder in Italy
BACKGROUND Depression has a lifetime prevalence of 10%-25% among women and 5%-12% among men. Selective serotonin reuptake inhibitors (SSRIs) are the most used and the most cost-effective treatment for long-term major depressive disorder. Since the introduction of generic SSRIs, the costs of branded drugs have been questioned. The objective of this study was to assess the cost-effectiveness (€ p...
متن کاملEscitalopram: a pharmacoeconomic review of its use in depression.
UNLABELLED Escitalopram (Cipralex), a new highly selective serotonin reuptake inhibitor (SSRI), is the active S-enantiomer of RS-citalopram. It is effective in the treatment of patients with major depressive disorder (MDD) and may have a faster onset of therapeutic effect than citalopram. It has also been shown to lead to improvements in measures of QOL. Escitalopram is generally well tolerated...
متن کاملEscitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression
The present randomized, double blind, parallel group, controlled, multi-centric trial was designed to evaluate the efficacy and tolerability of escitalopram in comparison with citalopram and sertraline in the treatment of major depressive disorder. Outpatients (N=214) with an ongoing/newly diagnosed ICD-10 major depressive episode and a Hamilton Rating Scale for Depression (HAM-D) score of > 18...
متن کامل